SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 31, 2000
PHARMACEUTICAL FORMULATIONS, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-11274 22-2367644
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
460 PLAINFIELD AVENUE, EDISON, NEW JERSEY 08818
(Address of Principal Executive Offices, including Zip Code)
Registrant's telephone number, including area code: 732-985-7100
N.A.
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
ITEM 5 OTHER EVENTS
The Company made the June 30, 2000 interest payments due under its 8
1/4% Convertible Subordinated Debentures Due 2002. Such payments were within the
time period allowed before such nonpayment would become an event of default
under the debenture indenture.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMACEUTICAL FORMULATIONS, INC.
By: /S/ R. BRADLEY CONNER
------------------------------
Name: R. Bradley Conner
Title: Vice President
Chief Financial Officer
Dated: August 11, 2000
